Most women with excessive hair growth (hirsutism) also experience a common type of non-scarring hair loss called Androgenetic alopecia with telogen effluvium.
Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
Microneedling should target depths of 0.5mm to 1.5mm for hair loss, with weekly sessions at 1mm recommended. Combining microneedling with Minoxidil is common for improved results.
Finasteride users reported improvements in hair appearance, including increased thickness, shine, and darker color. Some users noticed their hair looked healthier and less sunburned after starting the treatment.